COLGATE ORAL PHARMACEUTICALS DIVISION INCLUDES OTC, Rx UNITS: the company's professional oral care division, to be called the Colgate Oral Pharmaceuticals Division, includes the operations of Vipont Pharmaceuticals, acquired in 1990, and Colgate Hoyt/Gel- Kam. Within the division, the newly-established OTC unit has marketing responsibilities for Precision floss, Peroxyl mouthrinse, Orabase oral protectant, Fluorigard fluoride mouthwash, Viadent toothpaste and mouth rinse, and Viajet oral irrigation products. The prescription products unit has marketing responsibilities for the Gel-Kam, PreviDent, and Phos-Flur brands as well as Colgate toothbrushes and other products being detailed to the dental profession by the company's professional sales force. Establishment of the new structure is intended to allow the oral pharmaceuticals group to "focus on and penetrate the professional and retail segments simultaneously," the firm said. In conjunction with the realignment, Les Lewis has been named director of sales, North America, for the retail OTC business and Bob King has been appointed director of sales, North America, for the professional market. Commenting on the new structure, Jim Leach, commercial director of prescription products, said that the "Colgate/Viadent synergy positions us to deal more effectively with our customers on a day-to-day basis. As a company, we're able to leverage Viadent's retail broker network which will give Colgate Oral Pharmaceuticals a better retail presence with Peroxyl and Orabase. Likewise, the Viadent team now has access to our nationwide profesional sales force, which will strengthen the brand's presence among the dental profession."
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.
In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.
The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.
